Select the drug indication to add to your list


Pulmonary hypertension
Only 4 drugs may be compared at once

Generic Name and Formulations:

Selexipag 200mcg, 400mcg, 600mcg, 800mcg, 1000mcg, 1200mcg, 1400mcg, 1600mcg; tabs.

Select therapeutic use:

Indications for UPTRAVI:

Pulmonary arterial hypertension (PAH) (WHO Group 1) in patients with WHO functional Class II–III symptoms, to delay disease progression and reduce the risk of hospitalization for PAH.


Swallow whole; may take with food to improve tolerability. Initially 200mcg twice daily; increase by 200mcg increments twice daily at weekly intervals to highest tolerated dose up to 1600mcg twice daily; reduce to previous dose if not tolerated. Moderate hepatic impairment (Child-Pugh class B): initially 200mcg once daily; increase in 200mcg increments once daily at weekly intervals as tolerated.


Not established.


Concomitant strong CYP2C8 inhibitors (eg, gemfibrozil).


Discontinue if pulmonary veno-occlusive disease confirmed. Severe hepatic impairment (Child-Pugh class C): avoid. Pregnancy. Nursing mothers: not recommended.

Pharmacological Class:

Prostacyclin receptor agonist.


See Contraindications. May be potentiated by concomitant moderate CYP2C8 inhibitors (eg, teriflunomide, deferasirox); consider less frequent or reduced dosing. May be antagonized by concomitant CYP2C8 and UGT 1A3 or 2B7 inducers (eg, rifampin); increase up to twice the dose.

Adverse Reactions:

Headache, diarrhea, nausea, jaw pain, vomiting, pain in extremity, myalgia, flushing, arthralgia, rash, anemia, decreased appetite.

Generic Availability:


How Supplied:

Tabs 200mcg—60, 140; 400mcg, 600mcg, 800mcg, 1000mcg, 1200mcg, 1400mcg, 1600mcg—60; Titration pack—1 (140 x 200mcg tabs) + (60 x 800mcg tabs)

UPTRAVI 1600mcg tablets (Qty:60)

appx. price $16784.00